Cancer immunology and immunotherapy
著者
書誌事項
Cancer immunology and immunotherapy
（Current topics in microbiology and immunology, v. 344）
Springer, c2011
大学図書館所蔵 件 / 全7件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes bibliographical references and index
収録内容
- Immune infiltration in human cancer: prognostic significance and disease control / W.H. Fridman ... [et al.]
- Subversion and coercion: the art of redirecting tumor immune surveillance / J.B. Mumm and M. Oft
- STAT3: A target to enhance antitumor immune response / H. Lee ... [et al.]
- Biology and clinical observations of regulatory T cells in cancer immunology / M.W. Teng ... [et al.]
- Concepts and ways to amplify the antitumor immune response / B. Rubin and J.E. Gairin
- Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin / L.E. Kandalaft ... [et al.]
- Adoptive cellular therapy / S.A. Grupp and C.H. June
- Dendritic cell subsets as vectors and targets for improved cancer therapy / K. Palucka ... [et al.]
- Identification of human idiotype-specific T cells in lymphoma and myeloma / J. Weng ... [et al.]
- Modulation of CTLA-4 and GITR for Cancer Immunotherapy / F. Avogadri ... [et al.]
- Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways / S. Wang and L. Chen
- LAG-3 in cancer immunotherapy / M.V. Goldberg and C.G. Drake
- Immunologically active biomaterials for cancer therapy / O.A. Ali and D.J. Mooney
- Erratum to: Identification of human idiotype-specific T cells in lymphoma and myeloma / J. Weng ... [et al.]
内容説明・目次
内容説明
The interplay between tumors and their immunologic microenvironment is complex, difficult to decipher, but its understanding is of seminal importance for the development of novel prognostic markers and therapeutic strategies. The present review discusses tumor-immune interactions in several human cancers that illustrate various aspects of this complexity and proposes an integrated scheme of the impact of local immune reactions on clinical outcome. Current active immunotherapy trials have shown durable tumor regressions in a fraction of patients. However, clinical efficacy of current vaccines is limited, possibly because tumors skew the immune system by means of myeloid-derived suppressor cells, inflammatory type 2 T cells and regulatory T cells (Tregs), all of which prevent the generation of effector cells. To improve the clinical efficacy of cancer vaccines in patients with metastatic disease, we need to design novel and improved strategies that can boost adaptive immunity to cancer, help overcome Tregs and allow the breakdown of the immunosuppressive tumor microenvironment.
目次
Immune infiltration in human cancer: prognostic significance and disease control.- Subversion and coercion - The art of redirecting tumor immune surveillance.- STAT3: A target to enhance antitumor immune response.- Biology and clinical observations of regulatory T cells in cancer immunology.- Dendritic cell subsets as vectors and targets for improved cancer therapy.- Identification of human idiotype-specific T cells in lymphoma and myeloma.- Modulation of CTLA-4 and GITR for cancer immunotherapy.- Immunologically active biomaterials for cancer therapy.- Subject index
「Nielsen BookData」 より
